Acetylator Status on Tuberculosis Patients Receiving Isoniazid-Contained Antituberculosis Regiment

Hepatotoxic incidence after tuberculosis treatment might reach 48 %. Isoniazid was the most important antituberculosis related to hepatotoxic effect. One of the important risk factor related to hepatotoxic is acetylator status that reflects the metabolism rate of isoniazid in the body. Slow acetylator was proven as significant risk factor of hepatotoxic effect after tuberculosis treatmment. The acetylator status is related to genetic variation on NAT2 gene, whereas genetic variation of NAT2 gene is strongly related to ethnic or race. This study aimed to study the acetylator status on tuberculosis patients receiving isoniazid-contained antituberculosis regiment. Acetylator status was analyzed from the NAT2 genotypes (NAT2*5, NAT2*6 and NAT2*7). Detection of NAT2*5, *6, and *7 genotypes was performed using PCR/RFLP technique. From 35 DNA samples isolated from tuberculosis patients receiving antituberculosis, as many as 8 subjects (22.9 %) and 27 subjects (77.1 %) were categorized as slow acetylator and rapid acetylator, respectively. The dominant acetylator status in tuberculosis patients was rapid acetylator.